Commercial Benefits. CEPI is required by its own funders to obtain a share of any Awardee’s Commercial Benefits as a contribution to support CEPI’s programme activities. For clarity, examples of Commercial Benefits include the sales of a Project Vaccine at market prices, commercial licensing of Project IP, receipt of government-granted incentives such as Priority Review Vouchers and revenue from the commercialisation of combination, derivative or follow-on products (including antibody products, assays and vaccines) or application of production technology resulting in whole or part from CEPI funding.
Commercial Benefits. The Parties each agree that the benefits accruing to Bioamber pursuant to this Agreement are not limited to the rights granted pursuant to Sections 2.1.1 and 2.1.2 under the Sublicensed Patents. The Parties each agree that as a primary consideration Bioamber receives additional commercial benefits, including, without limitation, benefits from having access to the Licensed Intellectual Property as allowed hereunder, the reduction or abatement of research expenses that Bioamber would incur absent to access to the Licensed Intellectual Property, the forbearance obligations on DuPont (as set forth in Sections 2.7.1 through 2.7.1.b, inclusive, and being able to perform Hydrogenation, as licensed hereunder, earlier in time than Bioamber would have been able to do absent the access to the Licensed Intellectual Property as allowed hereunder.
Commercial Benefits. The specimens exported and their derivative products or intangible benefits will not be patented or used for commercial benefit. However, should any unforeseen commercial potential arise, the terms of its exploitation will be negotiated with the Uganda Wildlife Authority and in consultation with the Uganda National Council for Science and Technology. The use of the specimens will be exclusively for the purpose described in this agreement.
Commercial Benefits. CEPI is required by its own funders to obtain a share of any awardee’s Commercial Benefits as a contribution to support CEPI’s programme activities. As used in this Agreement, “Commercial Benefits” means any economically quantifiable benefits that arise from the commercial exploitation of the Project Results (including the Project Vaccine) other than in preparation for or in response to the Outbreak. Examples of Commercial Benefits include the sales of a Project Vaccine for market, commercial licensing of Project IP, receipt of government-granted incentives such as Priority Review Vouchers and revenue from the commercialization of combination, derivative or follow-on products (including antibody products, assays and vaccines) or application of production technology resulting in whole or part from CEPI funding.
Commercial Benefits. Ownership : Allocation for Remainder of Restated Program The Parties hereby agree that for the period which commenced on January 1, 1995 and for the remainder of the Restated Program, or until earlier termination as provided for hereunder, that the ownership of the commercial benefits and division of any profits of the collaboration shall be divided on an ongoing basis in accordance with the cumulative approved Restated Program costs for each Party at the time regardless of whether such costs are paid or reimbursed by a third party to the Party incurring those costs.
Commercial Benefits. The Parties each agree that the benefits accruing to Bioamber pursuant to this Agreement are not limited to the rights granted pursuant to Sections 2.1.1 and 2.1.2
Commercial Benefits
